MedTrace Logo

Effect of PUR003 on Asthma

NCT00989521 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2011-11-22

No results posted yet for this study

Summary

PUR003 is an inhaled substance that is proposed to assist in the treatment of asthma.

Study objectives are to :

1. to evaluate the safety of PUR003 in subjects with asthma, and
2. to evaluate the efficacy of PUR003 in assisting the treatment of asthma.

Conditions

  • Asthma
  • Lung Diseases
  • Bronchial Diseases

Interventions

DRUG

PUR003

PUR003 for inhalation

DRUG

Placebo

Normal saline for inhalation

Sponsors & Collaborators

  • St. Joseph's Healthcare Hamilton / Firestone Institute for Respiratory Health

    collaborator UNKNOWN

  • McMaster University

    collaborator OTHER

  • Pulmatrix Inc.

    lead INDUSTRY

Principal Investigators

  • Parameswaran Nair, MD, PhD · St. Joseph's Healthcare Hamilton / Firestone Institute for Respiratory Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00989521 on ClinicalTrials.gov